CLEVELAND, OH (WOIO) - A team of Cleveland State University researchers has developed a potentially groundbreaking treatment that has been shown to greatly improve the effectiveness of a brain tumor-fighting drug.
"Two-thirds of brain cancer patients die within five years of diagnosis, and the risks and side effects from current treatments can be nearly as bad as the disease itself," said Dr. Anthony Berdis, associate professor of chemistry and biology at CSU and a member of the University's Center for Gene Regulation in Health and Disease (GRHD), in a prepared statement. "The combination of our drug with temozolomide has the potential to greatly improve both life expectancy and the quality of life for patients."
Berdis' team is conducting additional toxicity studies on the therapeutic agent, which will be required for future FDA approval.
They will also soon begin tests on additional cancerous tumors to assess the effectiveness of the agent in treating breast cancer, leukemia and other diseases.
The research has been funded by the Department of Defense, the Ohio Third Frontier Commission, CSU's Office of Research, GRHD and Dr. John C. Vitullo's pilot and bridge funding program.
"This research could have tremendous applications for addressing numerous types of cancers and ultimately helping patients live longer, better lives," Berdis adds.